Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'
Novartis reported first-quarter sales of $13.1 billion, falling short of analyst expectations. The decline was attributed to the rapid erosion of sales from key medications due to generic competition. The company anticipates a challenging first half of the year but expects growth to pick up in the latter half.
- ▪First-quarter sales were $13.1 billion, below the expected $13.5 billion.
- ▪Sales of heart drug Entresto fell 42% following the expiration of its U.S. patent.
- ▪Novartis experienced a 1% year-on-year decline in sales, driven by generic competition.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | CNBC |
| Canonical URL | https://www.cnbc.com/2026/04/28/novartis-ceo-stock-earnings-mfn-trump-drug-pricing-policy.html |
| Publication time | Tue, 28 Apr 2026 07:23:34 GMT |
| Retrieval time | 2026-04-28T07:36:37.929Z |
| Last seen | 2026-04-28T07:36:37.929Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | Qpma4mEZbCmy |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
The Swiss company posted first-quarter sales of $13.1 billion, below the $13.5 billion expected by analysts polled by FactSet and reflecting a 1% decline year-on-year. Sales declined by 5% on a constant currency basis. Earnings per share came in at $1.65, down 10% year-on-year. The miss was driven by faster-than-expected generic erosion of the company's best-selling medicines Entresto, Promacta, and Tasigna, which each missed by between 7% and 17%, according to Citi analysts. The sales decline was only partially offset by the growth of newer medicines like breast cancer treatment Kisqali and multiple sclerosis drug Kesimpta.Sales of heart drug Entresto fell 42% after its U.S. patent expired. It faces loss of exclusivities in Europe later this year.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at CNBC.
Discussion
0 commentsMore from CNBC
